Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay (COVID-IDNow)
Covid19
About this trial
This is an interventional diagnostic trial for Covid19 focused on measuring Covid19, SARS-CoV2, Diagnosis performance
Eligibility Criteria
Inclusion Criteria:
- Patient aged ≥ 18 years
- Patient presenting to the emergency room of the GhPSJ and for whom a PCR examination is prescribed by the emergency doctor in charge of the patient
- French-speaking patient
- Patient affiliated with social security or, failing that, with another health insurance system
- Patient capable of giving free, informed and express consent.
Exclusion Criteria:
- Pregnant or breastfeeding patient.
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient under legal protection.
Sites / Locations
- Groupe Hospitalier Paris Saint-Joseph
Arms of the Study
Arm 1
Other
Screening patients COVID-19 test
As part of the patient's management, two nasopharyngeal swabs will be taken from the same nostril: The first swab will be sent to the microbiology laboratory for analysis with the Simplexa ™ COVID-19 Direct assay so as not to impact the patient's diagnostic result. The second swab taken as part of the research will be analyzed with the ID NowTM COVID-19 test located in the UAS by one of the nurses trained and authorized to use it. The choice to perform the ID Now ™ COVID-19 test in the emergency room and not in the laboratory is based on the supplier's instructions. Indeed, the nasopharyngeal swab is intended to be analyzed directly and not to be transported in a container which could hinder the quality of the sample. The discomfort or pain felt by the patient during the first sample can possibly influence the quality of the second. This could induce a bias. To minimize this bias, staff will be specifically trained in sampling.